Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The team from the University of California found that immunization with either Pfizer-BioNTech’s BNT162b2 or Moderna’s mRNA-1273 vaccine-induced enrichment of spike-specific B cells.
The viral spike protein mediates the initial stage of the SARS-CoV-2 infection process and is the primary target of antibodies following natural infection or vaccination.
Ilhem Messaoudi and colleagues say that vaccination also activated CD4 T cells and induced robust antigen-specific polyfunctional CD4 T cell responses.
Furthermore, clonally expanded CD8 T cells were observed in all vaccine recipients.
A pre-print version of the research paper is available on the bioRxiv* server, while the article undergoes peer review.
Vaccination and infection provide two different pathways to immunity
Since the COVID-19 outbreak first began in December 2019 in Wuhan, China, intense global efforts to rapidly develop effective vaccines against the causative agent SARS-CoV-2 have led to the emergency use authorization of several vaccines.
These include the messenger RNA- (mRNA) based vaccines developed by Pfizer (BNT162b2) and Moderna (mRNA-1273). Findings from clinical trials indicated that a 95% maximal protection is achieved within 1 to 2 months following the second dose of either vaccine, including protection against several circulating SARS-CoV-2 variants of concern.
However, the mechanisms by which these vaccines elicit long-lasting cellular immune responses to the virus remain poorly understood.
Natural infection and vaccination provide two different pathways to immunity, which studies have previously shown to be characterized by distinct T and B cell responses.
“Additional studies that integrate functional, transcriptional, and repertoire analysis of the memory immune cell response to COVID-19 mRNA vaccination are needed,” writes Messaoudi and colleagues.
What did the researchers do?
The team used single-cell RNA sequencing and functional assays to assess humoral (antibody) and cellular responses to two doses of either the Pfizer-BioNTech or Moderna mRNA vaccine (14 days following a second dose) in four individuals. The results were compared with the immune responses observed in three convalescent individuals who had experienced asymptomatic or mild infection.
What did the study find?
Both infection and vaccination induced anti-SARS-CoV-2 binding and neutralizing antibodies.
These antibodies were detected as early as two weeks following a first vaccine dose, with levels increasing several-fold after a second dose.
While neutralizing antibody titers following the first vaccine dose were comparable to those among convalescent individuals, significantly higher levels were observed in the vaccinees following the booster dose.
However, several important B cell adaptations were shared between vaccinees and convalescent individuals.
Analysis by flow cytometry revealed a reduction in the level of naïve B cells, but an expansion of memory B cells in both groups.
Additionally, single-cell RNA sequencing showed a reduction in IgA+ memory B cells following vaccination, a finding that has recently been described for convalescent individuals.
News
How to program DNA nanorobots to poke and prod cell membranes
Scientists have worked out how to best get DNA to communicate with membranes in our body, paving the way for the creation of ‘mini biological computers’ in droplets that have potential uses in biosensing [...]
Targeting cancer at the nanoscale
Scientists from the Department of Nuclear Medicine and Tracer Kinetics at Osaka University developed a novel system for targeted cancer radiation therapy that uses gold nanoparticles labeled with astatine-211. Owing to the limited range [...]
Introduction of Nanobomb into Tumor Could Inhibit Growth of Primary Tumors
Reactive oxygen species (ROS) exhibit the potential to act as signal carriers during the development of malignant tumors. At a suitable concentration, ROS tends to mediate cell growth and signal transduction. But ROS are [...]
How Nanotechnology Will Help Us Probe the Brain in Unimaginable Detail
One of the biggest challenges when it comes to probing and manipulating the brain are the blunt tools we have at our disposal. But breakthroughs in nanotechnology could soon change that, say researchers. Neuroscience has [...]
First controllable nanoscale gas-liquid interface fabricated
When liquid meets gas, a unique zone forms. Variable by nature, molecules can cross from one state to another, combining in unique ways to either desirable or unwanted ends. From heat escaping a mug [...]
Offshoot of Covid Delta variant on the rise in England
A newly detected coronavirus variant is on the rise in England, with the virus believed to be an offshoot of Delta. According to a briefing from the UK Health Security Agency, released on Friday, [...]
New testing strategy rapidly quantifies transmissibility of COVID-19 variants
A team of researchers has developed a new nanomechanical technique for fast, one-step, immune-affinity tests, which can quantify the immune response induced by different COVID-19 variants in serum. Their technique provides a new tool [...]
New Method Developed for 3D Printing Living Microbes To Enhance Biomaterials
Lawrence Livermore National Laboratory (LLNL) scientists have developed a new method for 3D printing living microbes in controlled patterns, expanding the potential for using engineered bacteria to recover rare-earth metals, clean wastewater, detect uranium, [...]
Researchers use AI to Develop Tool for Predicting Cancer Nanomedicine Outcomes
Nanomedicines may offer clinicians a way to deliver precise, targeted therapy directly to tumors without damaging surrounding tissue. Yet, progress in the development of new drugs that treat cancer at the nanoparticle level has [...]
Mito warriors: Scientists discover how T cell assassins reload their weapons to kill and kill again
Cambridge researchers have discovered how T cells—an important component of our immune system—are able keep on killing as they hunt down and kill cancer cells, repeatedly reloading their toxic weapons. Cytotoxic T [...]
Russians ‘have a hard time trusting their own vaccine,’ expert says
Sunday, October 3, set records for the most COVID-19 deaths in Russia on a single day. Only 29% of people in Russia are vaccinated, despite the country being the first to approve a vaccine. [...]
Nanosilver is not a ‘silver bullet’ in long-term treatment of infections
New research from the University of Technology Sydney (UTS) has found that pathogens that form biofilms can evolve to survive nanosilver treatment. The study is the first to demonstrate that long-term nanosilver treatment can [...]
Delta variant has 235% higher risk of ICU admission than original virus
New variants of SARS-CoV-2 are more virulent and transmissible than the original variant of the virus. Health experts associate these variants of concern (VOCs) with increased risk of hospitalization, intensive care unit (ICU) admission, [...]
Pathogen-Sensing Mask Could Detect COVID Infection
Freeze-dried genetic circuits could reveal the presence of SARS-CoV-2, Ebola, MRSA, and more. Masks and testing have been key to the COVID-19 pandemic response—and now devices that combine the two may be on the [...]
Neuroscientists Built an Ultra Detailed Map of the Brain Motor Cortex
Hundreds of neuroscientists built a ‘parts list’ of the motor cortex, laying groundwork to map the whole brain and better understand brain diseases. Before you read any further, bring your hand to your forehead. [...]
Can butterfly wings help detect COVID-19 faster?
An international team, led by Swinburne University of Technology and Australian National University (ANU), have made a breakthrough discovery that could potentially lead to faster, more accurate molecular or virus tests, including for COVID-19. [...]
